Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib

Documenti analoghi

• Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia
  di: Gunawan, Arief S., et al.
  Pubblicazione: (2017)
• Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series
  di: Stevens, Brett, et al.
  Pubblicazione: (2015)
• CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia
  di: Cui, Yajuan, et al.
  Pubblicazione: (2014)
• Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia
  di: Stahl, Maximilian, et al.
  Pubblicazione: (2016)
• Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis
  di: Arends, Christopher Maximilian, et al.
  Pubblicazione: (2020)